Patent for EntreMed's cell electroporation:
This article was originally published in Clinica
EntreMed has obtained a US patent on its 'electroporation chamber', a method of permeating tissue cells with therapeutic substances ex vivo. Cincinnati University researchers are using the device to insert the oxygenation-enhancing drug inositol hexaphosphate (IHP) into red blood cells. They plan clinical trials in which the IHP-treated cells are infused back into patients as a treatment for angina and other conditions due to inadequate tissue oxygenation.
You may also be interested in...
Feature: Public Health England has revealed it is only a week away from approving a COVID-19 antibody test for distribution via Amazon. HBW Insight looks at the race to place the first, government-approved coronavirus home-test on the UK market.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Execs On The Move: New Global Comms Boss At Siemens; CRH CEO Now Also Chair; New CEO At ChroniSense Medical
German multinational firm Siemens picks a global communications head; CRH Medical CEO also takes on chairmanship; ChroniSense Medical, a developer of medical monitoring devices, hires a new CEO; and more.